본문 바로가기
주메뉴 바로가기
Immunology
About Us
Core Technology Platforms
Pipeline
INVESTORS
Careers
ENG
KOR
ENG
Shaperon
About Us
Company Overview
Our History
CEO Message
Ethical Management
Organization Chart
Vision
Partners
Directions
Core Technology Platforms
Inflammasome
NanoMab
AIDEN
Publications
Pipeline
Line Up
NuGel
NuCerin
NuSepin
NuPulin
AI-based drug discovery
Papiliximab
Ovizumab
Investors
IR Announcements
IR Library
Disclosure
Press Release
News Room
Media Room
Careers
Corporate Culture & Our People
Recruitment
About Us
Company Overview
Our History
CEO Message
Ethical Management
Organization Chart
Vision
Partners
Directions
Core Technology Platforms
Inflammasome
NanoMab
AIDEN
Publications
Pipeline
Line Up
NuGel
NuCerin
NuSepin
NuPulin
AI-based drug discovery
Papiliximab
Ovizumab
Investors
IR Announcements
IR Library
Disclosure
Press Release
News Room
Media Room
Careers
Corporate Culture & Our People
Recruitment
pipeline
HOME
pipeline
Line Up
pipeline
Line Up
NuGel
NuCerin
NuSepin
NuPulin
AI-based drug discovery
Papiliximab
Ovizumab
Inflammasome Inhibitors
Pipeline
Indication
HIT
Lead optimization
Clinical Candidate
GLP tox
CMC
Ph1
Ph2
NuGel
Atopic Dermatitis
TO
NuSepin
COVID-19 Pneumonia
IV
NuCerin
Alzheimer’s Disease
PO
NuPulin
Idiopathic Pulmonary Fibrosis
PO
NuBesin
Obesity
PO
AI-based drug discovery
Alopecia Areata
TO
Obesity
PO
NanoMab
Pipeline
Indication
HIT
Lead optimization
Clinical Candidate
GLP tox
CMC
Ph1
Ph2
Papiliximab
(Anti-PD-L1xCD47)
Acute Myeloid Leukemia
IV
Ovizumab
(Anti-CD3, 4-1BB, TAA)
Solid Cancer
PO